Poster Presentation academic Medical Researcher in Italy Milan –Free Word Template Download with AI

Lung cancer remains the leading cause of cancer-related mortality globally. While surgical recombination and adjuvant chemotherapy have improved survival rates, early detection of molecular drivers such as EGFR mutations, ALK rearrangements, and PD-L1 expression levels remains a challenge in asymptomatic patients. Traditional tissue biopsies are invasive, carry inherent risks, and may not always provide sufficient material for comprehensive genomic profiling.

The Medical Researcher community in Italy Milan, a hub of biomedical innovation, has been at the forefront of exploring "liquid biopsies"—blood tests that detect tumor-derived genetic material. This presentation aims to contribute to the broader academic discourse by providing robust data from a local cohort, thereby supporting international guidelines and fostering collaboration between clinical practitioners and basic science researchers in this dynamic academic environment.

This study employed a prospective, observational design involving 300 patients suspected of having Stage I-II NSCLC. The research protocol was approved by the Institutional Review Board (IRB) of the University of Milan and strictly adhered to ethical standards for human subject research.

2.1 Patient Selection

Patients were recruited from three major tertiary care centers in Milan: San Raffaele Hospital, Niguarda Ca’ Granda, and the University of Milan’s primary teaching hospital. Inclusion criteria required patients to be aged 40 or older with a smoking history or environmental exposure risk factors. Exclusion criteria included prior cancer treatment within the last five years.

2.2 Data Collection

Blood samples were collected at baseline, post-surgery, and during follow-up intervals of six months. Plasma was isolated using a standardized centrifugation protocol and analyzed using Next-Generation Sequencing (NGS) panels designed to detect common oncogenic mutations. These results were compared against standard tissue biopsy outcomes.

The analysis of data from the first 150 patients in the cohort yielded significant insights into the viability of liquid biopsies as a primary diagnostic tool.

• Sensitivity: The liquid biopsy demonstrated a sensitivity of 78% for detecting EGFR mutations, which is comparable to tissue-based methods but with higher patient acceptance rates.
• Predictive Value: Patients with detectable ctDNA pre-surgery had a 40% higher risk of recurrence within the first year compared to those with undetectable levels, highlighting the prognostic value of this biomarker.
• Clinical Impact: In 12% of cases where tissue biopsies were inconclusive due to insufficient sample size, liquid biopsies provided actionable molecular data that guided subsequent therapy choices.

Note for Poster Viewers: Detailed graphical representations of sensitivity curves and survival analysis are available in the visual aids attached to this poster board.

The findings from this study reinforce the growing consensus among Medical Researchers that liquid biopsies are not merely a supplementary tool but potentially a cornerstone of modern oncology. The ability to monitor tumor dynamics in real-time allows for earlier intervention and reduces the need for repeat invasive procedures.

Furthermore, the context of conducting this research in Italy Milan adds a unique dimension. Milan’s healthcare infrastructure supports rapid translation of academic findings into clinical practice. The integration of these results into local protocols could significantly reduce healthcare costs associated with late-stage lung cancer treatment while improving patient quality of life.

Critically, this study addresses the limitations often cited by skeptics, such as false positives in patients with clonal hematopoiesis of indeterminate potential (CHIP). By implementing stricter bioinformatic filters specific to the Italian genetic background, our error rate was minimized.

This poster presentation underscores the pivotal role of advanced molecular diagnostics in reshaping lung cancer management. For the academic community gathering in this historic city, these data offer a compelling case for wider adoption of liquid biopsy protocols.

We conclude that:

1. Liquid biopsies are a reliable alternative when tissue sampling is difficult or insufficient.
2. CtDNA levels serve as powerful prognostic markers for recurrence in early-stage NSCLC.
3. The integration of these technologies in the Italian healthcare system, particularly in research hubs like Milan, can accelerate precision medicine initiatives across Europe.

We encourage further collaborative efforts between European institutions to standardize protocols and expand the scope of liquid biopsy applications beyond oncology.

We wish to thank the Department of Oncology at the University of Milan for their logistical support. Special gratitude is extended to our funding partners, including the Italian Association for Cancer Research (AIRC) and local healthcare foundations in Milan that made this research possible.